Thesis
Here you’ll find research that sketches out themes and theses that I’m the most interested in. Below is the back catalog of the publicly published theses.
As always, if you’re interested in chatting about any of these below, please reach out!
Thesis: Special Opportunities in Biotech Markets
A special thanks to the Analogue Group, Ismail Mardin, John Sherwin, Jacob Goodwin, Vishal Sethi, Viraj Chhajed, Mack Healy, and Eli Casdin for their thoughts and feedback as part of the drafting process.
Thesis: Biotech is the business of capital efficiency
A special thanks to the Analogue Group, Jolie Gan, Vishal Sethi, Viraj Chhajed, and Wesley Keelan for their thoughts during the drafting process.
Thesis: Optionality in Biotech is Undervalued
This piece was guided by “A Framework for Understanding Optionality” from Shawspring Partners. Special thanks to Wesley Keelan and Shoumik Dabir for helping ideate as part of their “Liquid Venture for Public Markets strategy” and the Analogue Group for helping guide the piece with their framework on optionality.
Thesis: Anatomy of a Biotech Bear
This piece was guided by Howard Marks memos, “The Limits to Negativism”, “Bubble.com”, and “Taking the Temperature”; Bruce Booth blog posts, “Biotech Venture Creation”, “Biotech Risk Cycles”. Special thanks to Wesley Keelan on helping guide macro analyses.
Thesis: Biosecurity. Well, the lack thereof.
This piece was guided by the great work done by Andrew Hessel, Mackenzie Morehead, and James Lin. Read Andrew’s call to action to build the next Anduril for biosecurity here. Mackenzie has written great pieces on investing in biosecurity (part 1, part 2